Health Canada Blesses RPS Diagnostics’ FebriDx Test

Health Canada has issued a device license to RPS Diagnostics for its FebriDx test.

The diagnostic helps to identify a pathogen-induced immune response to viral or bacterial acute febrile respiratory infection with a fingerstick blood sample.

Results are available in 15 minutes, enabling the establishment of an effective patient treatment plan, RPS says.

The test detects heightened levels of Myxovirus resistance A, an intracellular protein that increases in when an acute viral infection is present. It also simultaneously tests for C-reactive protein, acute-phase protein that elevates in the presence of a bacterial infection. — Michael Cipriano